In comparison with previous supply of N-(4-aminobenzoyl)-B-alanine) to Signa, for these specific batches, do you identify that you performed any change in your manufacturing site, manufacturing process, packaging procedure, warehouse practice, warehouse address, containers and/or logistics distribution/shipment i.e. was there any change in any of the aforementioned criteria that may have contributed to the issue encountered by Signa?